PCIB.OL
Price:
$1.65
Market Cap:
$61.59M
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA ...[Read more]
Industry
Biotechnology
IPO Date
2008-06-23
Stock Exchange
OSL
Ticker
PCIB.OL
According to PCI Biotech Holding ASA’s latest financial reports and current stock price. The company's current PE Ratio is -3.93. This represents a change of -6.49% compared to the average of -4.20 of the last 4 quarters.
The mean historical PE Ratio of PCI Biotech Holding ASA over the last ten years is -11.39. The current -3.93 PE Ratio has changed 3.35% with respect to the historical average. Over the past ten years (40 quarters), PCIB.OL's PE Ratio was at its highest in in the March 2020 quarter at 88.39. The PE Ratio was at its lowest in in the December 2018 quarter at -50.99.
Average
-11.39
Median
-6.41
Minimum
-31.99
Maximum
-1.31
Discovering the peaks and valleys of PCI Biotech Holding ASA PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 430.52%
Maximum Annual PE Ratio = -1.31
Minimum Annual Increase = -75.74%
Minimum Annual PE Ratio = -31.99
Year | PE Ratio | Change |
---|---|---|
2023 | -3.86 | 171.00% |
2022 | -1.42 | -75.74% |
2021 | -5.87 | -59.03% |
2020 | -14.32 | -55.24% |
2019 | -31.99 | 48.26% |
2018 | -21.58 | -10.90% |
2017 | -24.22 | 248.75% |
2016 | -6.94 | 430.52% |
2015 | -1.31 | -45.23% |
2014 | -2.39 | -61.03% |
The current PE Ratio of PCI Biotech Holding ASA (PCIB.OL) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.72
5-year avg
-11.49
10-year avg
-11.39
PCI Biotech Holding ASA’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like PCI Biotech Holding ASA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like PCI Biotech Holding ASA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is PCI Biotech Holding ASA's PE Ratio?
How is the PE Ratio calculated for PCI Biotech Holding ASA (PCIB.OL)?
What is the highest PE Ratio for PCI Biotech Holding ASA (PCIB.OL)?
What is the 3-year average PE Ratio for PCI Biotech Holding ASA (PCIB.OL)?
What is the 5-year average PE Ratio for PCI Biotech Holding ASA (PCIB.OL)?
How does the current PE Ratio for PCI Biotech Holding ASA (PCIB.OL) compare to its historical average?